|
A multicenter phase II basket clinical trial of lurbinectedin (PM01183) in selected advanced solid tumors. |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Celgene; Chugai Pharma; ImClone Systems; Lilly; Merck KGaA; Millennium; Novartis; Roche/Genentech; Sanofi; Symphony Evolution; Taiho Pharmaceutical |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Roche Pharma AG |
Consulting or Advisory Role - Clovis Oncology; Roche Pharma AG |
Travel, Accommodations, Expenses - PIQUR |
|
|
Consulting or Advisory Role - Bayer; Eisai; Roche Pharma AG |
|
|
No Relationships to Disclose |
|
|
Honoraria - Janssen; Merck; PharmaMar; Roche Pharma AG; Sanofi |
Travel, Accommodations, Expenses - Janssen; PharmaMar; Roche Pharma AG |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - Novartis |
Travel, Accommodations, Expenses - Novartis |
|
|
Research Funding - Bayer; GlaxoSmithKline; NanoCarrier; Northwest Biotherapeutics; Novartis; Roche/Genentech |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Janssen |
|
|
No Relationships to Disclose |
|
|
|
|
Stock and Other Ownership Interests - Zeltia |
|
Consulting or Advisory Role - Novartis |
Research Funding - Lexicon; Novartis |
|
|
|
Stock and Other Ownership Interests - PharmaMar |
|
|
No Relationships to Disclose |